Skip to search formSkip to main contentSkip to account menu

ABT 335

Known as: ABT-335, ABT335 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Role of selective peroxisome proliferator‐activated receptor modulators in managing cardiometabolic disease: tale of a roller‐coaster
Atherogenic dyslipidaemia is a hypertriglyceridaemic phenotype, associated with increased plasma concentrations of small, dense… 
Highly Cited
2010
Highly Cited
2010
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
: Cardiovascular disease (CVD) represents the leading cause of mortality worldwide. Lifestyle modifications, along with low… 
2009
2009
ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans
ABT‐335 is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the… 
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
2008
2008
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins
Background and objective:Atherogenic lipid parameters in patients with mixed dyslipidaemia have been demonstrated to increase… 
Review
2008
Review
2008
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Background: Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia… 
2008
2008
205: ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed Dyslipidemia
2008
2008
215: Effects of ABT-335 in Combination with Rosuvastatin on Low-Density Lipoprotein Particle Size in Patients with Mixed Dyslipidemia
2008
2008
Abstract 3732: Long-Term Safety and Efficacy of ABT-335 (Fenofibric Acid) in Combination with Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)